LooneyRJAnolikJHCampbellD. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum2004; 50: 2580–2589.
2.
LeandroMJEdwardsJCCambridgeGEhrensteinMRIsenbergDA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum2002; 46: 2673–2677.
3.
RastetterWMolinaAWhiteCA. Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med2004; 55: 477–503.
4.
AnolikJSanzILooneyRJ. B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep2003; 5: 350–356.
5.
TanakaYYamamotoKTakeuchiT. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol2007; 17: 191–197.
6.
TokunagaMFujiiKSaitoK. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford)2005; 44: 176–182.
7.
TokunagaMSaitoKKawabataD. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis2007; 66: 470–475.
8.
LuTYNgKPCambridgeG. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum2009; 61: 482–487.
9.
IwataSSaitoKTokunagaM. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in long-term remission after B cell depletion therapy with rituximab. J Rheumatol2011; 38: 633–641.
10.
WellerSBraunMCTanBK. Human blood IgM “memory” B cells are circulating splenic marginal zone B cells harboring a prediversified immuno- globulin repertoire. Blood2004; 104: 3647–3654.
